- Company
- Potential changes to reimb policy for new anticancer drugs
- by Moon, sung-ho Jul 16, 2025 06:08am
- Multinational pharmaceutical companies are actively pursuing to secure reimbursement for their anti-cancer drugs as first-line treatment options. Based on accumulated clinical research, companies are competitively applying for reimbursement from the government, putting in all efforts to accomplish this by the second half of this year. R
- Company
- Polivy’s reimbursement for DLBLC will soon be reviewed
- by Eo, Yun-Ho Jul 15, 2025 06:08am
- Polivy, the first first-line treatment introduced for diffuse large B-cell lymphoma (DLBCL) in 20 years, is entering the first stage of its renewed bid for reimbursement in Korea. According to industry sources, Polivy (polatuzumab vedotin), a treatment developed by Roche Korea for relapsed or refractory diffuse large B-cell lymphoma (DLBC
- Policy
- Gov't pursues 'project to produce unstable supply drugs'
- by Lee, Jeong-Hwan Jul 15, 2025 06:08am
- The Ministry of Health and Welfare (MOHW) plans to continue its project of providing government funding for the production of drugs with unstable supply. The MOHW plans to proceed with the currently budgeted project to support one item, while also working to secure additional budget to support more items. A MOHW official recently met w
- Opinion
- [Reporter’s View]Biotech’s responsible approach to failure
- by Cha, Jihyun Jul 15, 2025 06:06am
- Cases of terminated licensing deals and halted clinical trials are on the rise in Korea's biotech sector. Recently, IntoCell announced that the licensing agreement for its ADC (antibody-drug conjugate) platform with ABL Bio had been canceled due to patent overlap issues. Prior to that, Orum Therapeutics voluntarily decided to halt clinical d
- Company
- Various immunotherapies attempt to treat Alzheimer’s
- by Son, Hyung Min Jul 15, 2025 06:06am
- A series of immunotherapy candidates are showing promise in the field of Alzheimer's disease treatment. With the limitations of existing antibody therapies becoming apparent, multinational pharmaceutical companies are attempting approaches targeting new immune pathways. In particular, pipelines targeting innate immune regulation, such as NK cell
- Company
- Omjjara’s reimbursement progress gains attention
- by Eo, Yun-Ho Jul 14, 2025 06:04am
- Attention is turning to whether progress will be made in the reimbursement listing process for the new myelofibrosis drug, Omjjara. Omjjara (momelotinib), a myelofibrosis treatment developed by GSK Korea, passed the Health Insurance Review and Assessment Service's Cancer Disease Review Committee in March and is currently awaiting submissi
- Company
- Aftermath of Januvia's price cut…MSD-CKD compensation fight
- by Son, Hyung Min Jul 14, 2025 06:04am
- Regarding transaction for price difference compensation following the drug price reduction for the diabetes treatment Januvia, Chong Kun Dang and MSD Korea have not reached agreement during negotiation for nearly two years. While the distribution industry continues to demand compensation for losses incurred due to the drug price cut, the lac
- Policy
- How Trodelvy was applied flexible ICER for innovativeness
- by Lee, Tak-Sun Jul 14, 2025 06:04am
- The ADC breast cancer drug Trodelvy (sacituzumab govitecan, Gilead), which was reimbursed in June for triple-negative breast cancer, was the first case in which the ICER (incremental cost-effectiveness ratio) threshold was flexibly applied in recognition of its innovation. So how did the Drug Reimbursement Evaluation Committee (DREC) of t
- Company
- Daiichi Sankyo and Ono Pharmaceutical see surge in sales
- by Son, Hyung Min Jul 14, 2025 06:03am
- Japanese pharmaceutical companies operating in South Korea saw overall sales growth last year. All seven companies surveyed achieved year-on-year sales growth, with Daiichi Sankyo Korea and Ono Pharma Korea leading the way with double-digit growth rates. However, in terms of operating profits, the companies showed mixed emotions. According to
- Policy
- Orphan drug 'Bylvay Cap' wins reimb approval after reeval
- by Lee, Tak-Sun Jul 14, 2025 06:03am
- 'Bylvay Cap,' which is being considered for the expedited reimbursement listing process as a designated drug for 'Pilot Project for Integration of Product Approvals, Reimbursement Coverage Reviews, and Drug Price Negotiations,' received reimbursement appropriateness decision after reevaluation. Consequently, Bylvay Cap will be subjected to ne
